INTRODUCTION {#s1}
============

Penile cancer is a rare tumors in the Europe and United States, with an incidence of less than 1.00 per 100,000 males \[[@R1]\]. However, it is still a major public health problem in non-Western countries, such as Uganda, Brazil, and India \[[@R2], [@R3]\]. The main pathology type( ≥95%) of penile cancer are squamous cell carcinomas (SCCs), and the lymph node metastasis (LNM) are considered as the most important predictors of survival \[[@R2]\]. In contrast with other genitourinary cancers, penileSCC is typically characterized by stepwise regional lymph node (LN) spread, which is clearly related to survival \[[@R1], [@R2], [@R4], [@R5]\]. Nevertheless, the outcomes vary among patients with pathologically proven nodal disease. In addition, the survival rates of these patients exhibit large variations according to the extent of nodal involvement \[[@R2], [@R4], [@R6]\]. Thus, the detection and treatment of these metastases as soon as possible and improved prediction of survival are important for clinicians managing these patients.

The stage, grade of differentiation and clinicopathological factors of a primary tumor are well known to be predictive factors for LNM and survival \[[@R2], [@R6], [@R7]\]. However, deciding to perform regional node dissection based solely on these characteristics leads to unacceptable false-negative and false-positive rates. Inguinal lymph node dissection (ILAD) alone is curative in many cases with minimal metastases \[[@R2]--[@R4], [@R6], [@R7]\]. Nevertheless, a considerable number of men with palpable nodes do not experience metastatic spread, and consequently, up to 80% may be overtreated \[[@R8], [@R9]\], with resulting high morbidity \[[@R10], [@R11]\]. However, following a wait-and-see policy in treatment of these patients poses the risk of metastasis development to a stage at which a cure is no longer possible \[[@R12]\]. Thus, increased understanding of the molecular factors and biological features is of paramount importance in penile SCC \[[@R13], [@R14]\].

Protein kinase CK2 is a highly conserved and ubiquitous serine/threonine kinase composing with two catalytic subunits and two regulatory subunits \[[@R15]\]. CK2 is as a multifunctional protein kinase that is widely distributed in substrates \[[@R16], [@R17]\]. Disruption of *Saccharomyces cerevisiae* genes encoding CK2 catalytic subunits is a lethal event, and it plays major roles in cell cycle progression, proliferation, and differentiation processes \[[@R18], [@R19]\]. In addition, the clinical significance of CK2α subunits have been assessed in human cancers \[[@R20]--[@R24]\]. Thus, CK2α is now considered a potential target in the treatment of human malignancy \[[@R25]\]. As we've seen, the prognostic significance of nuclear CK2α in penile SCC is still unknown.

In this pilot study, we evaluated CK2α expression in primary penile SCC. In addition, the relationships between CK2α expression and clinicopathologic features were examined, as well as the clinical prognostic value of CK2α in penile SCC.

RESULTS {#s2}
=======

After a median time of 25 mo (range 1--133 mo), 43 patients died of penile cancer. The patients' clinical characteristics are shown in Table [1](#T1){ref-type="table"}.

###### CK2α expression in penile SCC and its correlation with the clinicopathologic parameters

  Variable        No. (%) or variable unit   CK2α expression   *P*        DSS       *P*                                   
  --------------- -------------------------- ----------------- ---------- --------- ------------------ ------------------ ---------
  Age (Year)      52(24-82)                                               0.160                                           0.403
   \<52           78(49.7)                   32(40.0)          48(60.0)             74.5(64.1-84.9)    71.6(60.0-83.2)    
   ≥52            79(50.3)                   22(28.6)          55(71.4)             67.9(56.3-79.5)    58.5(43.2-73.8)    
  BMI (kg/m^2^)   22.6(14.2-36.7)                                         0.911                                           0.686
   \<22.6         78(49.7)                   26(33.3)          52(66.7)             70.2(59.2-81.2)    63.2(49.7-76.7)    
   ≥22.6          79(50.3)                   27(34.2)          52(65.8)             73.9(62.7-85.1)    67.7(54.6-80.8)    
  T No. (%)                                                               0.001                                           \<0.001
   ≤pT1           48(30.6)                   26(54.2)          22(45.8)             89.8(78.6-100.0)   89.8(78.6-100.0)   
   ≥pT2           109(69.4)                  27(24.8)          82(75.2)             64.4(54.8-74.0)    54.1(41.6-66.6)    
  N No. (%)                                                               \<0.001                                         \<0.001
   N0             74(47.1)                   40(54.1)          34(45.9)             90.3(82.7-97.9)    82.7(70.2-95.2)    
   N+             83(52.9)                   13(15.7)          70(84.3)             55.7(43.7-67.7)    49.5(36.8-62.2)    
  G No. (%)                                                               0.177                                           0.022
   G1             92(58.6)                   35(38.0)          57(62.0)             75.7(65.9-85.5)    75.7(65.9-85.5)    
   ≥G2            65(41.4)                   18(21.5)          47(78.5)             67.4(55.1-79.7)    51.1(34.0-68.2)    

Immunohistochemical analysis revealed that CK2α was expressed in both the cell nucleus and cytoplasm (Figure [1A, 1B](#F1){ref-type="fig"}), and cancer tissues were with high CK2α expression. Similar to the immunohistochemistry results, CK2α expression was significantly higher in the penile cancer tissues in 12 normal-tumor tissue pairs by Western blotting (Figure [2A, 2B](#F2){ref-type="fig"}) (*P*\<0.001). Additionally, quantitative real-time PCR results also proved that CK2α expression was significantly increased in the tumor tissues over the non-tumor ones (Figure [2C](#F2){ref-type="fig"}).

![CK2α expression in 12 selected tumor samples\
CK2α levels were measured by Western blotting and qPCR **(A** and **B)** and the mRNA levels were then compared between normal and cancer penile tissues **(C)**.](oncotarget-08-51542-g001){#F1}

![CK2α expression in penile cancer tissues\
Negative and positive results are shown in Panels **(A**-**D)**, respectively. **(A)** A positive of CK2α expression in penile cancer tissues (200×); **(B)** 400× magnification of the boxed area shown in **(A)**. **(C)** A negative of CK2α expression in penile cancer tissues (200×); **(D)** 400× magnification of the boxed area shown in **(C)**.](oncotarget-08-51542-g002){#F2}

These results indicated that CK2α expression was significantly correlated with the T stage (*P*=0.001) and N status (*P* \< 0.001). However, there was no significant association between nuclear CK2α expression and age, body mass index (BMI), or tumor grade. The associations between CK2α immunoreactivity and the clinicopathologic features are shown in Table [1](#T1){ref-type="table"}.

Table [1](#T1){ref-type="table"} showed that DSS was significantly associated with CK2α overexpression (*P* \< 0.001). The patients with higher CK2α expression had 3-year and 5-year DSS rates of 57.6% (46.4%-68.8%) and 49.2% (36.3%-62.1%), compared with rates of 97.9% (93.8%-100.0%) and 94.0% (85.6%-100.0%) in the patients with low CK2α expression (*P* \< 0.001, Figure [3](#F3){ref-type="fig"}).

![Disease Specific Survival analysis of 157 penile cancer patients stratified by CK2a immunoreactivity (positiveCK2α: final staining score of ≥6 ;negative CK2α: final staining score of \<6)\
All statistical tests were two-sided. Significance level: P\<0.001.](oncotarget-08-51542-g003){#F3}

The results of univariate analyses related to DSS are shown in Table [1](#T1){ref-type="table"}. They indicated that the T stage and N status (all *P* \< 0.001), tumor grade (*P*=0.022) and CK2α overexpression (*P*\<0.001) were significantly correlated with DSS. Further, Cox multivariate analysis revealed that CK2α overexpression was an independent prognostic predictor (Table [2](#T2){ref-type="table"}, *HR*=8.234, *95% CI*=1.912-35.460*, P*=0.005). CK2α overexpression showed the best predictive accuracy for the LR, C-index and AIC among the basic factors. Accounting for CK2α expression, the predictive accuracy of the basic factors were with significantly increased (Table [3](#T3){ref-type="table"}).

###### Multivariate Cox regression analyses for DSS

  Variable                Multivariate analysis model                  
  ----------------------- ----------------------------- -------------- -------
  Age (age)                                                            
   \<52 vs ≥52            1.522                         0.818-2.833    0.185
  BMI (kg/m^2^)                                                        
   \<22.6 vs ≥22.6        0.693                         0.376-1.275    0.238
  T                                                                    
   ≤T1 vs ≥T2             5.335                         1.615-17.625   0.006
  N                                                                    
   N0 vs N+               2.534                         1.127-5.699    0.025
  G                                                                    
   G1 vs ≥G2              1.319                         0.710-2.450    0.369
  CK2α expression                                                      
   Negative vs Positive   8.234                         1.912-35.460   0.005

###### Predictive accuracy of factors

  Variable                                LR\*     AIC       C-index   Bootstrap C-index
  --------------------------------------- -------- --------- --------- -------------------
  T (≤T1 vs ≥T2)                          18.604   169.740   0.662     0.667
  N (N0 vs N+)                            20.631   167.710   0.696     0.702
  G (G1 vs ≥G2)                           5.021    183.320   0.599     0.597
  CK2α expression(negative vs positive)   27.827   160.520   0.700     0.699
  T+CK2α expression                       38.675   151.670   0.776     0.777
  N +CK2α expression                      36.378   153.970   0.766     0.765
  G+CK2α expression                       31.307   158.870   0.750     0.750

\*Logistic, AIC=Akaike information criterion, LR=likelihood ratio, C-index=concordance index.

DISCUSSION {#s3}
==========

CK2α expression has been assessed in a part of turmors, including prostate, colorectal and lung cancers \[[@R20]--[@R24]\]. However, with limited clinical data, the clinical significance of CK2α hasn\'t been studied. In the pilot study, we investigated the expression of CK2α in penile tissues from patients with penile cancer.

To our knowledge, CK2α expression in human penile tissues is unknown, and it has not yet been measured in human penile cancer. In the present study, significant differences in CK2α expression were detected between penile cancer tissues and non-tumor tissues (Figure [2](#F2){ref-type="fig"}). Several reports have consistently demonstrated that the CK2 level are increased in a variety of cancers \[[@R22], [@R23]\]. A recent study has shown that nuclear CK2α expression in tumor colorectal tissues was significantly increased compared with that in non-tumor colorectal ones \[[@R22]\]. Another previous study involving cancer has demonstrated that CK2α accumulates in cancer cells and plays a key role in promoting cell survival \[[@R20]\]. Some studies considered that increasing CK2α expression might be related to the increased proliferative capacity of tumor cells \[[@R25]--[@R28]\].

For the first time, the results of our study showed that CK2α overexpression was closely correlated with the pathologic tumor status (*P*=0.001) and pathologic nodal status (*P*\<0.001) (Table [1](#T1){ref-type="table"}). Although the mechanisms underlying these associations of CK2α are still unclear, these correlations are supported by several current lines of evidence. Mottet et al. have shown that blocking of the activation of hypoxia-inducible factor-1 (HIF-1) leads to CK2 overexpression and subsequent VEGF-C inhibition \[[@R29]\]. In addition, HIF-1 has been shown to stimulate the expression of VEGF-C, which is associated with the development of LNM \[[@R30]\]. Timofeeva et al. have reported that signal transducers and activators of transcription (STATs) which plays a critical role in Wilms' tumor are downstream targets of CK2 \[[@R31]\]. Constitutively, activation of STATs, which play the key role in the growth and differentiation, facilitate neoplastic behaviors of a number of cancers \[[@R32], [@R33]\]. Yao et al. have showed that CK2 activity suppresses cell proliferation and even induces cell death in both LNCaP and PC-3/AR human prostate cancer cells compared with mock-transfected control cells \[[@R21]\]. As a CK2 catalytic subunit, CK2α may play an important role in the marked resistance of cancer cells to apoptotic signals. This array of cellular responses is broadly orchestrated by CK2-dependent regulation of key signaling molecules in the Hedgehog/Gli, NF~K~B, Wnt, PI3K/AKT/mTOR and hypoxia pathways that have been multifunction \[[@R34]--[@R37]\].

Our study also demonstrated that CK2α expression can function as an independent of prognostic markers for penile cancer (Tables [2](#T2){ref-type="table"} and [3](#T3){ref-type="table"}). However, clinical data pertaining to the clinic value of CK2α are limited. Laramas et al. had shown that CK2α protein expression is elevated in prostate cancer by immunohistochemical analysis only \[[@R38]\]. In 2011, Lin et al. demonstrated that overexpression of nuclear CK2α in colorectal cancer tissues was correlated with several clinicopathologic factors and that it could be used as an independent prognostic marker for colorectal cancer \[[@R22]\]. Further, a study in which global gene expression profiling was performed on 190 human tumors of 14 cancer types resulted in the identification of 11 genes, including CK2, and the results suggested that the expression of CK2 was strongly correlated with that of MT1-MMP, in direct association with tumor prognosis \[[@R39]\]. However, no report of the prognostic significance of CK2α in penile SCC has done. Importantly, our results showed that CK2α overexpression could be used as an independent prognostic marker for penile cancer. In addition, accounting for CK2α expression in multivariate analysis of the basic factors had a positive impact on predictive accuracy (Table [3](#T3){ref-type="table"}).

In summary, this pilot study revealed that high CK2α expression was significantly associated with prognosis in penile cancer treated with surgery. Thus, patients with penile cancer exhibiting CK2α overexpression should be carefully monitored.

PATIENTS AND METHODS {#s4}
====================

Patients {#s4_1}
--------

After being approved by the institutional review board, patients with penile carcinoma treated at Sun Yat-sen University Cancer Center from March 2002 to March 2013 were retrospectively analyzed. A total of 43 patients presented with neoadjuvant chemotherapy and/or radiotherapy, and 87 presented with metastatic disease. Patients were excluded if they had received palliative therapy or if their pathological data were incomplete. Ultimately, 157 patients with bilateral ILND were included in the study population.

The non-tumor tissues were obtained by separation of the grossly normal tissues from the tumor tissues in the resected specimens. After uropathological review, the pathologic features were determined anew according to the AJCC 7th TNM staging system. The histological grade was classified according to the Broder system. Long term follow - up: every 3 month for the first 2 yr after surgery, every 6 mo during the 3rd -4th years, and then once yearly thereafter. The follow-up deadline was December 2015.

Immunohistochemistry and interpretation {#s4_2}
---------------------------------------

Mastadenoma and omission of the primary antibody were used as positive and negative control. 3% H~2~O~2~ was using for blocking endogenous peroxidase for 10 min, and 10% normal goat serum was using for blocking nonspecific binding of immunoglobulins for 10 min. With appropriately diluted primary antibodies, sections were placed at 4°C for one night. The slides were subsequently incubated with a primary antibody, clonal anti-CK2α (Millipore, Massachusetts, USA 1:50 dilution) at 25°C for 30 minutes. After 5-8 minutes incubation with 3,3′-diaminobenzidine, the sections were counterstained with hematoxylin and microscopic analysis.

Two pathologists was independently scored immunoreactivity. Nuclear and cytoplasmic staining were both scored for the sake of the ubiquitous and nucleo-cytoplasmic distribution of CK2α. According to the percentage of positive staining area, the score were 0 (0%), 1 (1-20%), 2 (21-50%), 3 (51-75%), and 4 (76-100%). And the following scores were used: 0 = no staining; 1+ = weak staining; 2+ = moderate staining; and 3+ = strong staining. The sum of the intensity and extent scores range 0 to 7. For the final statistics, tumors with score of ≥6 were considered positive (+) for CK2α. All other tumors were considered negative (-).

Quantitative real-time PCR {#s4_3}
--------------------------

12 tumor and non-tumor pairs of colorectal tissues using for RNA with an RNA extraction kit (TAKARA, Dalian, China). RNA quality was analyzed using an Agilent Stratagene Bioanalyzer (Palo Alto, California, USA). The RNA integrity numbers (RINs) of all 24 samples indicated that the RNA quality was good, and the samples were then used for cDNA synthesis, after which they were stored at -20°C until further use. The amplification mixture (25 μl) contained 0.030 ng cDNA (3 μl), 1× TaqMan Master Mix, and 1× TaqMan Gene Expression Assay Primer/Probe Mix (TAKARA, Dalian, China). The thermal cycling parameters were as follows: 40 cycles at 95°C for 2 min, 95°C for 30 sec, 60°C for 30 sec, and 72°C for 30 s for pre-denaturation, denaturation, annealing and extension, respectively. The sequences of the primers used for PCR amplification designed according to GenBank mRNA sequences were TGTTCGTCATGGGTGTGAAC (forward) and ATGGCATGGACTGTGGTCAT (reverse).

Western blot {#s4_4}
------------

The mixture of protease and phosphatase inhibitors (50 mM Tris-HCl, pH 7.5, 1% Triton X-100, 150 mM NaCl, 1 mM NaF, 1 mM Na~3~VO~4~, 10 mM sodium pyrophosphate, 1 mM phenylmethylsulfonyl fluoride, 1 lg/ml aprotinin and 1 lg/ml leupeptin) were useing for protein extracts. Extracted protein should be centrifugated at 14,000 g to remove debris. Denatured proteins in the samples were subjected to 10% SDS-PAGE. Anti-CK2α polyclonal antibody (1:1500 dilution) and phosphate-buffered serum (PBS:5% milk +0.05% Tween-20) was using for blocking at 25°C room temperature overnight. GAPDH (Sigma, 1:1500 dilution) was used as an internal control. Subsequently, goat anti-rabbit antibody (1:5000 dilution) was using for incubation for 1 hour at 25°C room temperature. Targeted proteins was enhanced with chemiluminescence reagents (Millipore). All experiments were conducted three times independently.

Statistical analysis {#s4_5}
--------------------

Receiver operating characteristic (ROC) curves were generated to identify the best point for prediction of patient prognosis. The correlations between CK2α expression and the clinicopathologic parameters were examined using Pearson\'s correlation analysis. DSS was calculated using the Kaplan-Meier method, and assessed by log-rank tests. Univariate and multivariate Cox proportional hazard regression analyses were performed to determine the impacts of the clinical and pathological factors on patient DSS with removal of nonsignificant factors in a stepwise backward fashion. Likelihood ratios (LRs), Akaike information criterion (AIC) values, and concordance indexes (C-indexes) were investigated to evaluate the accuracies of the factors. Bootstrap-corrected c-indexes were used for internal validation to better gauge expected future predictive accuracy (with sampling 1000 times). All data were analyzed using R2.11.1 (<http://www.r-project.org>), with statistical significance set at P\<0.05.
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